ScoreWhy is Parmax Pharma Ltd ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of -14.30% and Operating profit at 6.65% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 0.66
2
The company has declared Negative results for the last 4 consecutive quarters
- PAT(9M) At Rs -3.39 cr has Grown at -50.12%
- NET SALES(Latest six months) At Rs 7.64 cr has Grown at -31.23%
- PBT LESS OI(Q) Lowest at Rs -2.30 cr.
3
Risky - Negative EBITDA
- The company has recorded a negative EBITDA of Rs. -3.58 cr
- Over the past year, while the stock has generated a return of 41.64%, its profits have fallen by -306.9%
- The stock is trading risky as compared to its average historical valuations
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Parmax Pharma for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Parmax Pharma
41.64%
0.44
94.57%
Sensex
-9.49%
-0.74
13.06%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-14.30%
EBIT Growth (5y)
-225.63%
EBIT to Interest (avg)
0.66
Debt to EBITDA (avg)
0.22
Net Debt to Equity (avg)
-2.36
Sales to Capital Employed (avg)
2.35
Tax Ratio
100.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
-18.25%
ROE (avg)
5.12%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
34
Price to Book Value
-3.97
EV to EBIT
-6.65
EV to EBITDA
-8.54
EV to Capital Employed
4.65
EV to Sales
2.52
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-46.12%
ROE (Latest)
Negative BV
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend1What is working for the Company
EPS(Q)
Highest at Rs -1.55
-12What is not working for the Company
PAT(9M)
At Rs -3.39 cr has Grown at -50.12%
NET SALES(Latest six months)
At Rs 7.64 cr has Grown at -31.23%
PBT LESS OI(Q)
Lowest at Rs -2.30 cr.
Loading Valuation Snapshot...
Here's what is working for Parmax Pharma
Earnings per Share (EPS) - Quarterly
Highest at Rs -1.55
in the last five quartersMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (Rs)
Here's what is not working for Parmax Pharma
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs -2.30 cr has Fallen at -265.08%
Year on Year (YoY)MOJO Watch
Near term PBT trend is very negative
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Nine Monthly
At Rs -3.39 cr has Grown at -50.12%
Year on Year (YoY)MOJO Watch
Near term PAT trend is very negative
PAT (Rs Cr)
Net Sales - Latest six months
At Rs 7.64 cr has Grown at -31.23%
Year on Year (YoY)MOJO Watch
Near term sales trend is negative
Net Sales (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
Lowest at Rs -2.30 cr.
in the last five quartersMOJO Watch
Near term PBT trend is negative
PBT less Other Income (Rs Cr)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
